Latest Germany News

EcoGraf has identified a potential 20% increase in Epanko’s Stage 1 production capacity, while contracted European offtake has doubled to 40,000 tonnes per annum. The company is advancing debt financing and downstream plans, but its higher-output case remains outside the current financing base case.

Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.

Everest Metals’ Mt Edon project has been selected as Australia’s representative site in a five-year German-funded exploration program and accepted into the European Union’s Raw Materials Mechanism. The recognition may improve access to technical expertise, strategic partners and potential financing, although no funding, offtake or development commitment was announced.

Neu Horizon Uranium has defined a more than 2 km electromagnetic conductor at Storvallflon, where five exploration datasets converge on the strongest surface uranium response recorded during its 2026 campaign. The ASX-listed explorer plans 4,000 metres of diamond drilling in the first quarter of 2027, subject to approvals.

Altech Batteries expects to receive A$5.8 million net from a Malaysian land sale, but the liquidity boost arrives alongside the collapse of its CERENERGY project and insolvency at its German subsidiary. A €2 million bond repayment has also been pushed out at a higher interest rate.

BLS Pharmaceuticals has started FY27 with its strongest quarter on record, reporting A$26.7 million in unaudited revenue and positive operating cash flow. The company reaffirmed its A$105 million to A$115 million revenue guidance while continuing to invest in Australian and Scottish manufacturing capacity.

Atlas Arteria’s proportional toll revenue fell 0.4% in the September quarter excluding foreign exchange, while a proposed French tax package could have added about €210 million to APRR Group costs under 2025 conditions. Stronger US and German traffic provided some offset, but the company remains exposed to weak French light-vehicle demand and uncertain legislation.

BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.

Energy Fuels has amended its proposed acquisition of VAC after a customer dispute escalated into arbitration and lender forbearance at VAC’s US magnet plant. The filing also reveals VAC’s six-month net loss of €57.4 million, substantial debt and reliance on shareholder support ahead of the proposed transaction.

Memphasys has reported record September-quarter invoiced revenue of A$211,000 as its Felix fertility device moves into more international markets. The commercial progress comes alongside A$3.5 million in funding, but the loan still requires shareholder approval for conversion into notes.

ECS Botanics is taking six Australian-grown medicinal cannabis flower products into the UK through Curaleaf Laboratories, with initial supply targeted for November. The two-year deal offers access to UK sell-through but no guaranteed volumes, revenue or minimum purchases.

Altech Batteries reported a $43.4 million FY2026 loss after abandoning its two major German battery projects, while its CERENERGY subsidiary filed for insolvency and a proposed Malaysian asset sale fell through. The company now faces substantial doubt about its ability to continue as a going concern.